News | Proton Therapy | January 07, 2016

Proton Therapy Sales Just Over $1 Billion in 2015

Global sales were more than double those of 2014; 1,200-1,800 treatment rooms predicted worldwide by 2030

MEDraysintell, proton therapy, global sales 2015

January 7, 2016 — MEDraysintell noticed that in 2015 global proton therapy sales orders grew to record levels at just over $1 billion for a total of 58 proton therapy treatment rooms, more than twice as much as in 2014. Two companies together commanded almost half of these orders.

There is an increasing interest for one-room compact proton therapy centers, which accounted for about 35 percent of the global orders.
By the end of 2015, 174 particle therapy treatment rooms were operational worldwide, and projections by 2030 anticipate the proton therapy world market to reach between 1,200 and 1,800 treatment rooms worldwide.
There is growing clinical evidence regarding the efficacy of particle therapy that will progressively be used to treat a broader number of indications, according to MEDraysintell. Therefore, there is now a clear positive stance on the future of the proton therapy market, and this technology is becoming a real part of the global radiotherapy world.
A complete analysis of the global proton therapy market is provided in the third edition of the World Proton Therapy market report from MEDraysintell. The report, which is a 250-page comprehensive review of the market dynamics on a world basis, analyzes both past and future trends up to the year 2030. The report also contains a detailed profile of 20 promoters, manufacturers or developers of proton and carbon therapy equipment.

For more information:

Related Content

Sponsored Content | Videos | Radiation Therapy | January 18, 2019
Join Chris Toth, president of Varian’s Oncology Systems business, for a look at product introductions for 2018 plus
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.